SNT
Click for more information
2.44% 4.0¢ syntara limited

News: PXS Pharmaxis says Boehringer confirms phase 2 study for second disease indication will...

  1. Hot News
    191,598 Posts.
    lightbulb Created with Sketch. 2809
    clock Created with Sketch.
    15/05/17
    09:55
    Post #: 24686436

    May 15 (Reuters) - Pharmaxis Ltd (PXS)

    • In addition to a phase 2 trial in Nash that is scheduled to start midyear, Boehringer has confirmed that a phase 2 study for a second disease indication will commence this year
    Likes Created with Sketch. 2  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

TRP Tissue Repairs soars nearly 32% on TGA approval for wound healing gel
right-arrow Created with Sketch.
IGO IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity
right-arrow Created with Sketch.
NEWS Nine staff strike as Paris Olympic coverage begins
right-arrow Created with Sketch.
PEC Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil
right-arrow Created with Sketch.
1CG One Click Group surpasses $3M in revenue YTD with 40% growth
right-arrow Created with Sketch.
BGL Bellevue aims for 45% production increase by FY 2028, announces $150M placement
right-arrow Created with Sketch.
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
(20min delay)
Last
4.0¢ 		Change
-0.001(2.44%) 		Mkt cap ! $47.76M
Open High Low Value Volume
4.1¢ 4.2¢ 3.9¢ $28.84K 709.9K

Buyers (Bids)

No. Vol. Price($)
1 99807 3.9¢
 

Sellers (Offers)

Price($) Vol. No.
4.0¢ 99162 1
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.